Aimmune Therapeutics to Announce Fourth Quarter and Full Year 2015 Financial Results on Thursday, March 3, 2016

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that its financial results for the fourth quarter and full year 2015 will be released on Thursday, March 3, 2016, after the markets close. At 5:00 p.m. Eastern Time, Aimmune management will host a conference call to discuss its financial results and provide a general business update.

The conference call will be accessible via the company’s website at www.aimmune.com on the Events page under Investor Relations. Please connect to the company’s website at least 15 minutes prior to the start of the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 1-877-497-1438 (U.S.) or 1-262-558-6296 (international) and provide the conference call passcode 60127471 to join by phone.

A telephone replay will be available approximately two hours after the call’s completion until 11:59 p.m. Eastern Time on March 7, 2016. Access numbers for the telephone replay are 1-855-859-2056 or 1-404-537-3406; the passcode is 60127471. A webcast replay will also be archived on www.aimmune.com for 30 days.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for peanut allergy and other life-threatening food allergies. The company’s characterized oral desensitization immunotherapy (CODIT™) system, an approach to oral immunotherapy (OIT), uses rigorously characterized product candidates with gradual, controlled up-dosing protocols to obtain clinically meaningful desensitization to food allergens. Aimmune Therapeutics initiated the Phase 3 PALISADE trial of its lead product, AR101, a complex mixture of natural peanut proteins and pharmaceutical-grade ingredients for the treatment of peanut allergy, one of the most common food allergies, in early 2016. AR101 has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age. For more information, please see www.aimmune.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160225005707/en/